Edwards Lifesciences upgraded to Buy from Hold at Stifel
Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...
Stifel raises Edwards Lifesciences stock to buy, target to $90
Stifel analysts upgraded Edwards Lifesciences (NYSE:EW) stock from Hold to Buy, citing potential growth acceleration in the Transcatheter Aortic Valve Replacement (TAVR) market. The firm also ...
Forbes1d
Edwards Lifesciences
Edwards Lifesciences Corp. engages in the patient ... Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter ...
Edwards Lifesciences downgraded at Wolfe on TAVR worries
Edwards Lifesciences (NYSE:EW) traded lower in the premarket on Thursday after Wolfe Research downgraded the heart device maker, citing concerns over its prospects in the market for Transcatheter ...
Business Wire5d
EDWARDS LIFESCIENCES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Edwards Li…
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”) ...
Edwards Lifesciences downgraded to Underperform at Wolfe Research
Wolfe Research downgraded Edwards Lifesciences (EW) to Underperform from Peer Perform with a $60 price target The firm says its core ...